Compare Accenture plc (ACN) vs Incyte Corporation (INCY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Accenture plc vs Incyte Corporation — how do they compare? Accenture plc trades at $139.02 (market cap $86.98B), while Incyte Corporation trades at $116.91 (market cap $23.10B). The key difference: Accenture plc is far larger — about 3.8× Incyte Corporation's market cap, and Accenture plc pays a 4.59% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| ACN | INCY | |
|---|---|---|
Market Cap | $86.98B | $23.10B |
Sector | Technology | Health |
52-Week High | $303.33 | $118.05 |
52-Week Low | $124.41 | $67.38 |
Enterprise Value | $85.20B | $19.12B |
Dividend Yield | 4.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Accenture (ACN) trades at $136.96, down 0.28% on the day, with technical indicators showing a bearish bias despite recent earnings beats. The company reported strong revenue growth to $69.67B in 2025 with a net margin of 10.66%, supported by strategic AI partnerships announced in June 2026. Valuation ratios appear attractive with a P/E of 10.94 and EV/EBITDA of 6.65, while analyst consensus remains strongly bullish with a $193.92 price target.
The outlook is positive given consistent earnings outperformance, expanding AI-driven consulting partnerships, and solid cash flow generation. Key risks include competitive pressures in consulting services, execution challenges in integrating AI initiatives, and potential macroeconomic headwinds affecting client spending. The stock offers fundamental value with growth catalysts from digital transformation demand.
Incyte (INCY) trades at $118.05, up 1.02% today, with a bullish technical signal from moving averages and strong fundamental performance. Revenue grew to $5.14 billion in 2025, with net income surging to $1.29 billion and a robust net margin of 26.71%. Recent catalysts include the acquisition of Vega Therapeutics and positive regulatory updates for Opzelura in Europe, supporting momentum.
The outlook remains positive given earnings beats, expanding product portfolio, and analyst consensus leaning buy. Key risks include reliance on key drugs, regulatory hurdles, and competitive pressures. The stock trades above the consensus price target of $109.14, suggesting near-term consolidation potential amid overbought RSI levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Accenture plc
Accenture PLC provides management and technology consulting services and solutions. The Company delivers a range of specialized capabilities and solutions to clients across all industries on a worldwide basis. Accenture operates a network of businesses provides consulting, technology, outsourcing, and alliances.
Read more on ACN →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
